Therapeutics Advisory Group CCG and NHS Trusts in Norfolk and Waveney Index of TAG recommendations Generic name Indication BNFclass Trafficlight IQoro euromuscular training Hiatus hernia - improving symptoms No BNF entry - device Double Red Not recommended for device routine use / Not commissioned (L-) Carnitine Carnitine Deficiency 9.8.1 Drugs used in Red Hospital / Specialist metabolic disorders only (Para-)aminosalicylic acid Tuberculosis 5.1.9 Antituberculosis Double Red Not recommended for drugs - routine use / Not Antimycobacterials commissioned 5-fluorouracil + salicyclic acid Hyperkeratotic actinic keratosis 13.8.1 Photodamage Double-GreenSuitable for GPs to topical solution initiate and prescribe 5-fluorouracil 5% w/w cream Non-hypertrophic actinic keratosis 13.8.1 Photodamage Double-GreenSuitable for GPs to initiate and prescribe Abacavir HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist antiretroviral drugs only Abacavir + dolutegravir + HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist lamivudine antiretroviral drugs only Abacavir and lamivudine HIV infection in combination with other 5.3.1 HIV Infection Red Hospital / Specialist antiretroviral drugs only Abaloparatide Male and juvenile osteoporosis 6.6.1 Calcitonin and Double Red Not recommended for Calcitonin and routine use / Not parathyroid hormone commissioned Abatacept Rheumatoid arthritis - 1st line biologic 10.1.3 Drugs that suppress Red Hospital / Specialist after failure of non-biologic DMARDs - the rheumatic disease only as per NICE TA 280 process Abatacept Treatment of Juvenile Idiopathic 10.1.3 Drugs that suppress Red Hospital / Specialist Arthritis (JIA) as per NICE TA 373 the rheumatic disease only process Abatacept Rheumatoid arthritis - after other 10.1.3 Drugs that suppress Red Hospital / Specialist DMARDs including a TNF inhibitor - as the rheumatic disease only per NICE TA 195 process Abatacept Psoriatic arthritis after DMARDs as 10.1.3 Drugs that suppress Double Red Not recommended for per NICE TA 568 terminated appraisal the rheumatic disease routine use / Not process commissioned Abatacept moderate rheumatoid arthritis after 10.1.3 Drugs that suppress Double Red Not recommended for conventional DMARDs have failed as the rheumatic disease routine use / Not per TA715 process commissioned Abatacept (subcutaneous) First line biologic option for moderate 10.1.3 Drugs that suppress Red Hospital / Specialist to severe active rheumatoid arthritis in the rheumatic disease only adults who responded inadequately to process one or more DMARDS (including MTX) Abciximab Prevention of MI during PCTA - as per 2.9 Antiplatelet drugs Red Hospital / Specialist NICE TA 47 only Abemaciclib Locally advanced or metastic hormone 8.1.5 Other antineoplastic Red Hospital / Specialist receptor-positive, human epidermal drugs only growth factor receptor 2 (HER2)- negative breast cancer as first endocrine-based therapy in adults - as per NICE TA 563 Abiraterone Metastatic hormone-relapsed prostate 8.3.4 Hormone antagonists Red Hospital / Specialist cancer before chemotherapy is only indicated (in combination with prednisone or prednisolone) - as per NICE TA 387 Abiraterone acetate Castration resistant metastatic 8.3.4 Hormone Antagonists Red Hospital / Specialist prostate cancer previously treated with only docetaxel - as per NICE TA 259 Printed: 14 September 2021 Page 1 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Acalabrutinib chronic lymphocytic leukaemia as per 8.1.5 Protein kinase Red Hospital / Specialist TA689 inhibitors only Acamprosate Maintenance of abstinence in alcohol- 4.10.1 Drugs used in Red Hospital / Specialist dependent patients substance misuse only ACE inhibitors with Angiontensin-II Receptor 2.5.5.1 Angiotensin- Double red Not recommended for Antagonists (ARBs) - NICE Do Not Do converting enzyme routine use / Not inhibitors commissioned ACE Inhibitors - various Treatment of cor pulmonale - as per 2.5.5.1 Angiotensin- Double Red Not recommended for NICE CG 101 - NICE Do Not Do converting enzyme routine use / Not inhibitors commissioned Acitretin All indications 13.5.2 Oral retinoids for Red Hospital / Specialist psoriasis only Aclidinium bromide (Eklira Inhaled treatment for Chronic 3.1.2 Antimuscarinic Double-GreenSuitable for GPs to Genuair®) ▼ Obstructive Pulmonary Disease bronchodilators initiate and prescribe (COPD) Acne treatment - Aknicare® Treatment of acne Not listed Double Red Not recommended for products routine use / Not commissioned ActiPatch® Relief of musculoskeletal pain Not listed - pulsed Double Red Not recommended for electromagnetic routine use / Not stimulator commissioned Adalimumab Treatment of (non-radiographic) axial 10.1.3 Drugs that suppress Red Hospital / Specialist spondyloarthritis - as per local the rheumatic disease only treatment pathway process Adalimumab Juvenile idiopathic rheumatoid arthritis 10.1.3 Cytokine modulators Red Hospital / Specialist (JIA) - option in children with chronic only anterior uveitis - as per NHS England policy Adalimumab Behcet's syndrome 10.1.3 Drugs that affect the Red Hospital / Specialist rheumatic disease only process Adalimumab Anti-TNF treatment option for adult 10.1.3 Drugs that suppress Double Red Not recommended for patients with severe refractory uveitis - the rheumatic disease routine use / Not as per NHS England policy and NICE process commissioned TA 460 Adalimumab Treatment of adults with psoriasis - as 10.1.3 Drugs that suppress Red Hospital / Specialist per NICE TA 146 and the local the rheumatic disease only treatment pathway process Adalimumab 2nd line anti-TNF in patients with joint 10.1.3 Drugs that suppress Red Hospital / Specialist or skin autoimmune disease who the rheumatic disease only develop IBD on etanercept - as per process local treatment pathway Adalimumab Rheumatoid arthritis - after other 10.1.3 Drugs which suppress Red Hospital / Specialist DMARDs including a TNF inhibitor - as the rheumatic disease only per local treatment pathway process Adalimumab moderate rheumatoid arthritis after 10.1.3 Drugs that suppress Red Hospital / Specialist conventional DMARDs have failed as the rheumatic disease only per TA715 process Adalimumab Plaque psoriasis in children and young 10.1.3 Drugs that suppress Red Hospital / Specialist people - as per NICE TA 455 the rheumatic disease only process Adalimumab Severe active Crohn's disease which 1.5.3 Drugs affecting the Red Hospital / Specialist has not responded to conventional immune response only therapy - as per NICE TA 187 Adalimumab Ankylosing spondilitis - as per local 10.1.3 Drugs that suppress Red Hospital / Specialist treatment pathway the rheumatic disease only process Adalimumab Anti-TNF Alpha treatment option for 10.1.3 Drugs that suppress Double Red Not recommended for paediatric patients with severe the rheumatic disease routine use / Not refractory uveitis process commissioned Printed: 14 September 2021 Page 2 of 83 Index of TAG recommendations Generic name Indication BNFclass Trafficlight Adalimumab Moderate to severe hidradenitis 10.1.3 Drugs that suppress Red Hospital / Specialist suppurativa - as per NICE TA 392 the rheumatic disease only process Adalimumab Moderate to severe ulcerative colitis 1.5.3 Drugs affecting the Red Hospital / Specialist (primary) - as per NICE TA 329 immnune response only Adalimumab Treatment of children and young 10.1.3 Cytokine modulators Red Hospital / Specialist people with polyarticular juvenile only idiopathic arthritis and for enthesitis- related juvenile idiopathic arthritis as per NICE TA 373 Adalimumab Children with Severe Refractory 10.1.3 Cytokine modulators Red Hospital / Specialist Uveitis with onset in childhood (age 2 only or more up to 18 or less) - as per NHS England policy Adalimumab Treatment of psoriatic arthritis 10.1.3 Drugs which suppress Red Hospital / Specialist (including switching between the rheumatic disease only treatments) - as per local treatment process pathway Adalimumab (biosimilar) Peripheral spondyloarthritis - following 10.1.3 Drugs that suppress Red Hospital / Specialist use of 3 DMARDs, as per NNUH the rheumatic disease only application process ADHD drugs - various First-line use in children and 4.4 CNS stimulants and Double Red Not recommended for adolescents with ADHD - as per NICE drugs for ADHD routine use / Not CG 72 - Do Not Do commissioned ADHD drugs - various Use in pre-school children - as per 4.4 CNS stimulants and Double Red Not recommended for NICE CG 72 - Do Not Do drugs used for ADHD routine use / Not commissioned Afatinib ▼ Advanced squamous non-small-cell 8.1.5 Protein Kinase Double Red Not recommended for lung cancer after platinum-based Inhibitors routine use / Not chemotherapy - as per NICE TA 444 commissioned Afatinib ▼ Treatment of epidermal growth factor 8.1.5 Protein kinase Red Hospital / Specialist receptor mutation-positive locally inhibitors only advanced or metastatic non-small-cell lung cancer - as per NICE TA 310 Aflibercept Treatment of visual impairment due to 11.8.2 Ocular diagnostic and Red Hospital / Specialist myopic choroidal neovascularisation in peri-operative only adults - as per NICE TA 486 preparations Aflibercept Visual impairment caused by macular 11.8.2 Ocular diagnostic and Red Hospital / Specialist oedema after branch retinal vein peri-operative only occlusion - as per NICE TA 409 and preparations local treatment pathway Aflibercept Treatment of Diabetic Macular 11.8.2 Ocular diagnostic